APOA1 and Hepatic fibrosis: Figure 3 illustrates advanced liver fibrosis risk and fatty liver severity across TG/APOA1 quartiles (Q1:<2.24; Q2:2.24-3.33; Q3:3.34-4.95; Q4:>4.95) in participants with MAFLD. The results demonstrate a significant increase in the proportion of participants with intermediate or high-risk advanced liver fibrosis in the higher quartiles compared to the lower quartiles based on NFS (Figure 3A), FIB-4 (Figure 3B), and APRI (Figure 3C). Additionally, higher TG/APOA1 quartiles were associated with a higher prevalence of moderate or severe fatty liver (Figure 3D).